Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) or its ligand programmed cell death ligand-1 (PD-L1) have important potential in treating non-small-cell lung cancer (NSCLC) [1–5]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.